This is a summary of the European public assessment report (EPAR) for Vimpat. It explains how the Agency assessed the medicine to recommend its authorisation and its conditions of use. It is not intended to provide practical advice on how to use Vimpat.
For practical information about using Vimpat, patients should read the package leaflet or contact their doctor or pharmacist.
Vimpat : EPAR - Summary for the public (PDF/78.47 KB)
First published: 17/09/2008
Last updated: 22/09/2017
Vimpat : EPAR - Risk-management-plan summary (PDF/215.53 KB)
First published: 05/09/2019
|Agency product number||
|International non-proprietary name (INN) or common name||
|Therapeutic area (MeSH)||
|Anatomical therapeutic chemical (ATC) code||
UCB Pharma SA
|Date of issue of marketing authorisation valid throughout the European Union||
29/08/2019 Vimpat - EMEA/H/C/000863 - IB/0081/G
- Annex I - Summary of product characteristics
- Annex IIA - Manufacturing-authorisation holder responsible for batch release
- Annex IIB - Conditions of the marketing authorisation
- Annex IIIA - Labelling
- Annex IIIB - Package leaflet
Please note that the size of the above document can exceed 50 pages.
You are therefore advised to be selective about which sections or pages you wish to print.
Vimpat is indicated as monotherapy and adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy.